Skip to main content

Advertisement

SpringerLink
Log in

Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?

  • Invited Commentary
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Aromatase inhibitor-induced arthralgia (AIA) remains a significant clinical dilemma for breast cancer survivors and their oncologists. Approximately half of women who take aromatase inhibitors (AIs) experience joint pain which often affects daily functioning and quality of life. Effects can be so severe that many women stop taking the AI; nonetheless, we know very little about what causes AIA, or how to effectively treat it. This article briefly describes the syndrome of AIA and then discusses several potential management strategies for this frequent clinical quandary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Howell A et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2.

    Article  CAS  PubMed  Google Scholar 

  2. Group BIGC et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766–76.

    Article  Google Scholar 

  3. Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–92.

    Article  CAS  PubMed  Google Scholar 

  4. Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.

    Article  CAS  PubMed  Google Scholar 

  5. Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443–9.

    Article  CAS  PubMed  Google Scholar 

  6. Henry NL et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365–72.

    Article  CAS  PubMed  Google Scholar 

  7. Kadakia KC et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016;21(5):539–46.

    Article  PubMed  Google Scholar 

  8. Partridge AH et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–62.

    Article  CAS  PubMed  Google Scholar 

  9. Cuzick J et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9(12):1143–8.

    Article  CAS  PubMed  Google Scholar 

  10. Hadji P et al. Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol. 2012;23(10):2566–72.

    Article  CAS  PubMed  Google Scholar 

  11. Huober J, C.B., Wu J, et. al. Symptoms of endocrine treatment and outcome: a retrospective analysis of the monotherapy arms of the BIG 1–98 trial. In American Society of Clinical Oncology. 2011. Chicago.

  12. Stearns V et al. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol. 2015;33(3):265–71.

    Article  CAS  PubMed  Google Scholar 

  13. Liedke PE et al. New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole—analyses from NCIC CTG MA.17. Breast. 2016;27:99–104.

    Article  CAS  PubMed  Google Scholar 

  14. Egawa C et al. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. Int J Clin Oncol. 2016;21(2):262–9.

    Article  CAS  PubMed  Google Scholar 

  15. Sestak I et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866–72.

    Article  PubMed  Google Scholar 

  16. Mieog JS et al. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol. 2012;13(4):420–32.

    Article  PubMed  Google Scholar 

  17. Crew KD et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877–83.

    Article  PubMed  Google Scholar 

  18. Servitja S et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. Ther Adv Med Oncol. 2015;7(5):291–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Irwin ML et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.

    Article  PubMed  Google Scholar 

  20. Lahart IM et al. Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies. Acta Oncol. 2015;54(5):635–54.

    Article  PubMed  Google Scholar 

  21. Peppone LJ et al. The effect of YOCAS(c)(R) yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. Breast Cancer Res Treat. 2015;150(3):597–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Galantino ML et al. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther. 2012;11(4):313–20.

    Article  PubMed  Google Scholar 

  23. Jacobsen PB et al. Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer. Psychooncology. 2015;24(11):1578–80.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Khan N et al. Repeated assessment of orthotopic glioma pO(2) by multi-site EPR oximetry: a technique with the potential to guide therapeutic optimization by repeated measurements of oxygen. J Neurosci Methods. 2012;204(1):111–7.

    Article  PubMed  Google Scholar 

  25. Rastelli AL et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat. 2011;129(1):107–16.

    Article  CAS  PubMed  Google Scholar 

  26. Khan, Q.K., Bruce F., Reddy, PS; Sharma, P; Klemp, JR; Fabia, CJ, Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: the VITAL trial, in ASCO Annual Meeting. 2012: Chicago.

  27. Prieto-Alhambra D et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. 2011;125(3):869–78.

    Article  CAS  PubMed  Google Scholar 

  28. Shapiro AC et al. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Res Treat. 2016;155(3):501–12.

    Article  CAS  PubMed  Google Scholar 

  29. Crew KD et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010;28(7):1154–60.

    Article  CAS  PubMed  Google Scholar 

  30. Mao JJ et al. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer. 2014;50(2):267–76.

    Article  CAS  PubMed  Google Scholar 

  31. Oh B et al. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study. Acupunct Med. 2013;31(3):264–71.

    Article  CAS  PubMed  Google Scholar 

  32. Bao T et al. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat. 2013;138(1):167–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bae K et al. Acupuncture for aromatase inhibitor-induced arthralgia: a systematic review. Integr Cancer Ther. 2015;14(6):496–502.

    Article  PubMed  Google Scholar 

  34. Xepapadakis G et al. New views on treatment of aromatase inhibitors induced arthralgia. Breast. 2010;19(3):249–50.

    Article  PubMed  Google Scholar 

  35. Muslimani AA et al. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer. 2009;9(1):34–8.

    Article  CAS  PubMed  Google Scholar 

  36. Kubo M et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res. 2012;32(6):2331–6.

    CAS  PubMed  Google Scholar 

  37. Henry NL et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. 2011;117(24):5469–75.

    Article  CAS  PubMed  Google Scholar 

  38. Hershman DL et al. Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S0927. J Clin Oncol. 2015;33(17):1910–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Briot K et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127–34.

    Article  CAS  PubMed  Google Scholar 

  40. Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA

    Polly Niravath

Authors
  1. Polly Niravath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Polly Niravath.

Ethics declarations

Conflict of Interest

Polly Niravath declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niravath, P. Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?. Curr Breast Cancer Rep 8, 135–138 (2016). https://doi.org/10.1007/s12609-016-0217-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-016-0217-4

Keywords

Search

Navigation